SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

LUPIN

BSE: 500257 19 Aug 2025
Healthcare
₹ 1970.95
Lupin Ltd specializes in Pharmaceuticals within the Healthcare sector.

LUPIN - Share Price & Details

Market Cap
₹90,237
High /Low
2,403 / 1,774
Stock P/E
24.4
Book Value
₹377.0
Dividend Yield
0.61
ROCE
21.3
ROE
₹20.6
Face Value
2.0
PEG Ratio
0.41
EVEBITDA
₹15.5
Debt
5,448
CMP / FCF
60.0
Debt to equity
₹0.32
NP Ann
3,306
High price all time
2,403
Piotroski score
₹6.0
Graham Number
829.0
No. Eq. Shares
45.7
Net CF
₹560
Net profit
3,722
Price to book value
5.23
Interest Coverage
₹14.9
Low price all time
52.5
Industry PE
33.8
Reserves
₹17,112
Free Cash Flow
₹1,347

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
LUPIN LTD.57627.321280.757085.946.4890,23724.4
FORTIS HEALTHCARE LTD.4730.4518.84330.30.697170377.9
ABBOTT INDIA LTD.16,806.103,670.4016,045.90172.726951247.9

Peer Comparison Chart


About LUPIN

Lupin Ltd, with Security Code 500257, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin

(17 Aug 2025)
Astellas, Remegen, and Daewoong Pharma announced positive trial results for their respective drug candidates.
Read more →

Lupin to Conduct BE Study for Synthetic Semaglutide Tablets in 3 Strengths

(16 Aug 2025)
New Delhi: Lupin Limited has received the green light from the Subject Expert Committee (SEC) under the Endocrinology & Metabolism division...
Read more →

9% Interest Payable on GST Refunds if Not Released within 60 Days from Date of FAA’s Order: Bombay HC in Lupin Ltd Case [Read Order]

(13 Aug 2025)
The Court held that once the FAA's refund order attains finality, Section 56 of the CGST Act mandates compliance within sixty days,...
Read more →

Lupin Share Price Rises As Company Partners With Sandoz To Launch Biosimilar Ranibizumab Globally

(13 Aug 2025)
Lupin share price edged up to ₹1946.30 after announcing a deal with Sandoz to commercialise its biosimilar ranibizumab in key global markets...
Read more →

Lupin ties up with Sandoz to commercialise biosimilar product

(13 Aug 2025)
Lupin has partnered with Sandoz Group AG to commercialize its biosimilar ranibizumab across multiple regions, with Sandoz handling...
Read more →

Lupin announces licensing deal for Ranibizumab biosimilar

(13 Aug 2025)
Lupin announced it has entered into an agreement with Switzerland-based Sandoz Group AG to market and commercialise Lupin's biosimilar...
Read more →

Company Updates